Dr Morillo on Future Directions for Golcadomide in R/R Follicular Lymphoma

I don’t think [golcadomide] will fight against bispecific antibodies [for a spot in the follicular lymphoma treatment paradigm]. It will be a different alternative for different subsets of patients, but also, maybe in the future…I see possible combinations with [golcadomide and bispecific antibodies].

Daniel Morillo, MD, a consultant hematologist in the Lymphoma Unit and a clinical investigator at the Early Phase Clinical Trials Unit (START Madrid–FJD) at Hospital Universitario Fundación Jiménez Díaz, discussed future research directions for investigating the oral CELMoD golcadomide (CC-99282) in patients with relapsed/refractory follicular lymphoma, including its positioning relative to existing agents in the treatment paradigm and the potential for combining it with bispecific antibodies.

Golcadomide plus rituximab (Rituxan), which was evaluated in the phase 1/2 CC-99282-NHL-001 trial (NCT03930953), is an oral regimen that demonstrated the ability to control follicular lymphoma in heavily pretreated patients and was well tolerated, Morillo said. Because the regimen is oral, most patients can be treated outside a hospital setting, which could be particularly advantageous in community-based settings, where oral administration is easier than other modes, he noted.

In longer-term data from Cohort D of the CC-99282-NHL-001 trial, which were presented at the 2026 EHA Congress, golcadomide at 0.4 mg plus rituximab (n = 36) produced an objective response rate of 97% with a complete response rate of 75% at a data cutoff of February 26, 2026.

When examining where an agent like golcadomide could fit in the follicular lymphoma treatment paradigm, Morillo contended that rather than competing directly with bispecific antibodies, golcadomide could serve as a distinct alternative for different subsets of patients. He added that he sees potential in eventually combining golcadomide with bispecific antibodies, reasoning that achieving the best outcomes will require combining the best available agents, and that a bispecific-plus-golcadomide regimen could be one path toward that goal.